Cetuximab and the Head and Neck Squamous Cell Cancer

被引：31

作者：

Concu, Riccardo ^{[1
]}

Cordeiro, M. Natalia D. S. ^{[1
]}

机构：

[1] Univ Porto, Fac Sci, Dept Chem & Biochem, REQUIMTE, Rua Campo Alegre 687, P-4169007 Porto, Portugal

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2018年 / 18卷 / 03期

关键词：

Cell; Cancer; Cetuximab; Food and Drug Association; Cytotoxic T lymphocytes; Epidermal growth factors; GROWTH-FACTOR RECEPTOR; PLATINUM-BASED CHEMOTHERAPY; ANTIGEN-PROCESSING MACHINERY; MODULATED RADIATION-THERAPY; PHASE-II; HUMAN-PAPILLOMAVIRUS; PLUS CETUXIMAB; TARGETED THERAPY; RISK-FACTOR; CARCINOMA;

D O I：

10.2174/1568026618666180112162412

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.

引用

页码：192 / 198

页数：7

共 66 条

[1]

Ang KK, 2002, CANCER RES, V62, P7350

[2] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck [J].

Baselga, J ;

Trigo, JM ;

Bourhis, J ;

Tortochaux, J ;

Cortés-Funes, H ;

Hitt, R ;

Gascón, P ;

Arnellal, N ;

Harstrick, A ;

Eckardt, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5568-5577

[3] Preferential apoptosis of CD56dim natural killer cell subset in patients with cancer [J].

Bauernhofer, T ;

Kuss, I ;

Henderson, B ;

Baum, AS ;

Whiteside, TL .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (01) :119-124

[4] Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck [J].

Bernier, Jacques .

NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (12) :705-713

[5] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J].

Bonner, JA ;

Harari, PM ;

Giralt, J ;

Azarnia, N ;

Shin, DM ;

Cohen, RB ;

Jones, CU ;

Sur, R ;

Raben, D ;

Jassem, J ;

Ove, R ;

Kies, MS ;

Baselga, J ;

Youssoufian, H ;

Amellal, N ;

Rowinsky, EK ;

Ang, KK .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :567-578

[6] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival [J].

Bonner, James A. ;

Harari, Paul M. ;

Giralt, Jordi ;

Cohen, Roger B. ;

Jones, Christopher U. ;

Sur, Ranjan K. ;

Raben, David ;

Baselga, Jose ;

Spencer, Sharon A. ;

Zhu, Junming ;

Youssoufian, Hagop ;

Rowinsky, Eric K. ;

Ang, K. Kian .

LANCET ONCOLOGY, 2010, 11 (01) :21-28

[7] A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck [J].

Bowles, Daniel W. ;

Senzer, Neil ;

Hausman, Diana ;

Peterson, Scott ;

Vo, Alex ;

Walker, Luke ;

Cohen, Roger B. ;

Jimeno, Antonio .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) :1197-1203

[8]

Brakenhoff RH, 2017, RECENT RESULTS CANC, V206, P37, DOI 10.1007/978-3-319-43580-0_3

[9] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study [J].

Burtness, B ;

Goldwasser, MA ;

Flood, W ;

Mattar, B ;

Forastiere, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8646-8654

[10] Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial [J].

Caponigro, Francesco ;

Di Gennaro, Elena ;

Ionna, Franco ;

Longo, Francesco ;

Aversa, Corrado ;

Pavone, Ettore ;

Maglione, Maria Grazia ;

Di Marzo, Massimiliano ;

Muto, Paolo ;

Cavalcanti, Ernesta ;

Petrillo, Antonella ;

Sandomenico, Fabio ;

Maiolino, Piera ;

D'Aniello, Roberta ;

Botti, Gerardo ;

De Cecio, Rossella ;

Losito, Nunzia Simona ;

Scala, Stefania ;

Trotta, Annamaria ;

Zotti, Andrea Ilaria ;

Bruzzese, Francesca ;

Daponte, Antonio ;

Calogero, Ester ;

Montano, Massimo ;

Pontone, Monica ;

De Feo, Gianfranco ;

Perri, Francesco ;

Budillon, Alfredo .

BMC CANCER, 2016, 16

← 1 2 3 4 5 6 7 →